SAN DIEGO, March 22, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com), announced today that the European Patent Office (“EPO”) has issued an official decision to allow the Company’s patent application entitled, “Method for the Manufacture of Dodecyl 2-(N,N-Dimenthylamino)-Propionate.” The allowed patent application is a divisional of a Company-owned European patent issued in 2000 entitled “Crystalline Salts of Dodecyl 2-(N,N-Dimenthylamino)-Propionate” that protects the DDAIP.HCl compound and method of manufacture.
